Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2014

View Archived Issues

Baxter restructures agreement with Xenetic Biosciences and provides pipeline update

Researchers characterize antifungal activity EV-086

Glycopolymers used to uncover the mechanistic basis of tumor immunoprotection

Pazopanib demonstrates activity in patients with germ cell tumors

Sorafenib activity limited in patients with germ cell tumors

Chugai Pharmaceutical presents highlights of fourth quarter 2013

Phase II/III trial of Stallergenes' house dust mite immunotherapy tablets meets primary endpoint

AstraZeneca completes purchase of Bristol-Myers Squibb's global diabetes business

Burnet Institute receives grant to evaluate HIV test

Portola enters second collaboration with Bayer and Janssen for andexanet alfa

Chinese researchers present novel acetylcholinesterase inhibitors for Alzheimer's disease

New chimeric proteins patented by Biogen Idec and Amunix Operating

Omeros reports data from phase I trial of OMS-721

Phase Ib trial evaluates ONT-380 in breast cancer

Yong Guang Pharmaceutical discloses novel agents for cancer

U.S. group claims new HDAC4 inhibitors for Huntington's disease

Scientists in China synthesize new CETP inhibitors

Grastek obtains approval in Canada for grass pollen-induced allergic rhinitis

Tecfidera obtains approval in Europe for multiple sclerosis

Agios Pharmaceuticals opts for U.S. rights to IDH1 program

U.S. Navy approves phase I trial of Multikine in patients with HIV/HPV and perianal warts

FDA grants breakthrough therapy designation to eltrombopag

Tetrandrine demonstrates ability to protect against Ebola virus challenge in vivo

Ferrer collaborates with Ergomed and Ildong Pharmaceuticals for lorediplon

Kyowa Hakko Kirin initiates phase III study of ARQ-197 for HCC in Japan

Dainippon Sumitomo Pharma offers overview of third quarter of fiscal 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...